Table 2.
SLE patients, anti-IFNα autoantibodies and tuberculosis.
| Anti-IFNα | Age at diagnosis | Gender | SLE Treatment at TB | TB involvement | Other infection | ||||
|---|---|---|---|---|---|---|---|---|---|
| titer* | TB | SLE | Lung | LN | CNS | ||||
| 1 | < 3 | 20 | 42 | F | 0 | 1 | |||
| 2 | 65 | 49 | 53 | F | 0 | 1 | |||
| 3 | < 3 | 35 | 41 | F | 0 | 1 | Zona | ||
| 4 | < 3 | 37 | 35 | F | S, HCQ | 1 | |||
| 5 | 18 | 24 | 24 | F | 0 | 1 | |||
| 6 | 83 | 27 | 27 | F | 0 | 1 | |||
| 7 | 10 | 21 | 45 | F | 0 | 1 | 1 | ||
| 8 | < 3 | 64 | 63 | F | S, HCQ | 1 | |||
| 9 | < 3 | 52 | 53 | M | 0 | 1 | 1 | ||
S steroids, HCQ hydroxychloroquine, LN lymph node, CNS central nervous system, F, female, M male, TB tuberculosis, SLE systemic lupus erythematosus.
*Positivity threshold ≥ 10 UA/mL.